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Abstract
Purpose Infection near metal implants is a problem that presents challenging treatment dilemmas for physicians. The aim 
of this study was to analyse the efficacy of two treatment protocols for acute fracture-related infections.
Methods Seventy-one patients in two level-1 trauma centres in the Netherlands were retrospectively included in this study. 
These trauma centres had different standardised protocols for acute infection after osteosynthesis: 39 patients were selected 
from protocol A and 32 from protocol B. Both protocols involve immediate surgical debridement and soft tissue coverage, 
but differ in antibiotic approach: (A) immediate empirical combination antibiotic therapy with rifampicin, or (B) postponed 
(1–5 days) targeted antibiotic therapy. The primary outcome of these protocols was success, defined as a fracture healing in 
the absence of infection. The secondary outcome was antibiotic resistance patterns. Logistic regression was conducted on 
patients and treatment-related factors in association with primary success.
Results Primary success was achieved in 72% of protocol A patients, in 47% of those in protocol B (P = 0.033), and with 
prolongation of treatment success was achieved in 90% and 78% of patients, respectively. Protocol A exhibited a better pri-
mary success rate (adjusted OR 3.45, CI 1.13–10.52) when adjusted for age and soft tissue injury. There was no significant 
difference in antibiotic resistance between the two protocols.
Conclusion Both protocols yielded high overall success rates. Immediate empirical antibiotics can be used safely without 
additional bacterial resistance and may contribute to increased success rates.
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Introduction
Fracture-related infection (FRI) is a serious problem after 
operative fracture management. It is accompanied by 
increased morbidity, prolonged hospital stays, an increased 
number of operations and thereby a significant increase in 
healthcare costs [1]. FRI has an incidence of approximately 
1–2% in closed fractures and increases to up to 50% in severe 
open fractures [2–4].
Treatment regimens for prosthetic joint infections (PJI) 
are becoming increasingly well defined, but PJI differs sig-
nificantly from FRI in terms of the soft tissue problems 
and the need for fracture stability that accompany it, and 
evidence-based guidelines for FRI are currently insufficient 
[5]. Unfortunately, infection near orthopaedic implants 
seems to be highly complex and poorly described. This has 
resulted in a diverse collection of treatment protocols, with 
recommendations only for specific circumstances. Although 
aggressive surgical debridement seems to be embedded in 
most approaches, a consensus on standardised antibiotics or 
the retention of orthopaedic implants has yet to be reached 
[3, 6–8].
In a previous study, the effect of an aggressive stand-
ardised approach to FRI, which consisted of immediate 
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surgical debridement with hardware retention and com-
bination antibiotics with rifampicin, produced promis-
ing results. High overall success rates were achieved, but 
the implications of empirical antibiotics in the context of 
emerging resistance remain the subject of debate [9].
To contribute to the knowledge gap on this subject, we 
compared two standardised regimens that shared the phi-
losophy of a uniform approach to all acute FRI, includ-
ing all anatomic sites and fixation types. Both consisted 
of immediate aggressive debridement for source control, 
retention of orthopaedic implants and early soft tissue cov-
erage, but differed in their antibiotic treatment guidelines. 
The aim was to analyse the effect of the regimens in terms 
of success rates, microbiological aspects and emerging 
resistance.
Methods
Patient identification
A retrospective cohort study of patients who had been 
treated for FRI was performed in two level-1 trauma centres 
in the Netherlands. The inclusion period was from Janu-
ary 1, 2008 (hospital B) or January 1, 2011 (hospital A) 
until December 31, 2014. Patients were identified by diag-
nosis codes, operation registers and antibiotic administra-
tion. Patients of between 17 and 75 years of age with acute 
symptoms (< 3 weeks) of early and delayed FRI (< 10 weeks 
after fracture fixation) who had been treated according to 
the standardised treatment protocols were included in the 
study [10]. Infection was diagnosed through a combina-
tion of clinical and laboratory findings (redness, swelling, 
wound discharge, elevated leukocytes and/or CRP), purulent 
drainage, peroperative pus or microbiological identification. 
Exclusion criteria were as follows: symptoms for > 3 weeks 
upon presentation (due to biofilm maturation), chronic 
infections and/or immune suppressive state (e.g., chronic 
immunosuppressive medication, immune deficiencies) and 
removal of orthopaedic implants at first debridement. Patient 
and treatment characteristics were collected from patients’ 
files. This study was reviewed, and a waiver was provided 
by the local Medical Ethics Review Committee (METC), no. 
14/343. All procedures were performed in accordance with 
the principles of the Declaration of Helsinki.
Treatment protocols
Both protocols were followed in each hospital independently 
of the type of infection ([sub]acute or early/delayed), loca-
tion or fixation type.
Surgical treatment
In all patients, an early and thorough surgical debridement was 
performed as soon as possible after a (suspected) diagnosis of 
FRI. Surgical debridement was repeated as often as required 
by the attending surgeon. Orthopaedic implants were retained 
when they were stable and sufficient. Primary closure after 
debridement was the aim in every patient. In protocol B, a 
wound drain was used at the surgeon’s preference, while in 
protocol A, no drains were used. When primary closure could 
not be achieved, the alternative treatment in protocol A was to 
apply a vacuum dressing with secondary wound closure. In 
larger defects, secondary flap or skin transplants were consid-
ered. In protocol B, direct flap transplantation with or without 
a vacuum dressing was the preferred treatment.
Antibiotic treatment
Protocol A Empirical antibiotic therapy started immediately 
after the first debridement when cultures had been obtained. 
This consisted of 10 days of intravenous administration of anti-
biotics. The antibiotic therapy began with a combination of 
vancomycin and rifampicin. Vancomycin was chosen because 
of its activity against most common pathogens of FRI and 
its synergetic effect with rifampicin [11]. Vancomycin was 
adjusted when culture and susceptibility data were available. 
Rifampicin was continued if not otherwise contra-indicated. 
After the intravenous administration period, a combination of 
antibiotic therapy including rifampicin was orally continued 
for ten additional weeks, depending on the culture and sus-
ceptibility data.
Protocol B Antibiotic therapy started after culture data had 
become available (1–5 days) and consisted of a 14-day targeted 
intravenous administration period, followed by 4 weeks of oral 
antibiotic treatment. The type and administration (intravenous 
or oral) of antibiotics depended on bacterial identification and 
susceptibility data. Rifampicin was only administered when 
all cultured bacteria were susceptible.
In both protocols, patients were given a peroperative antibi-
otic prophylaxis, which in most cases consisted of a one-time 
administration of cephalosporin after cultures had been sam-
pled. In the case of repeated debridement, antibiotic therapy 
was continued in both protocols according to the culture results 
from the first debridement and was adjusted only when nec-
essary. No additional preoperative antibiotic prophylaxis was 
administered at redebridement.
Microbiology
From all patients, cultures (tissue, swab and fluid) were 
obtained during initial surgical debridement and were 
repeated with each additional surgery. Isolates were cultured 
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and identified using standard techniques. Susceptibility test-
ing was performed on isolates using the Phoenix automated 
susceptibility testing system, disk diffusion and/or E-test 
strips.
Initial resistance was defined as resistance before admin-
istration of the applicable antibiotic, while intrinsic resist-
ance was not considered to be initial resistance. Follow-up 
resistance was defined as resistance after the administration 
of the respective antibiotic, regardless of whether that patho-
gen had been cultured before. Overall resistance was defined 
as the combination of both abovementioned types.
Outcome measures
The primary outcome measure was success. Primary success 
was defined as resolved signs and symptoms of infection and 
fracture consolidation on radiological follow-up, as assessed 
by the treating physician after a single protocol run. In some 
cases, fracture consolidation as assessed on routine X-rays 
took longer than the duration of one protocol run. Therefore, 
the moment of fracture consolidation on follow-up X-rays 
was counted as the moment of success. Inflammatory mark-
ers were not part of the criteria for success because of their 
low sensitivity and specificity in the diagnosis of FRI, and 
they are not routinely measured in either protocol [12]. 
Overall success was defined as success after the prolongation 
of antibiotic treatment or repetition of the protocol (includ-
ing possible redebridement and/or antibiotics). A protocol 
was considered to be a failure if orthopaedic implants were 
removed, if a case of non-union occurred, or if amputation 
was performed.
The secondary outcome measure was the emergence of 
resistance against administered antibiotics. Microbiological 
characteristics and susceptibility patterns were described.
Statistical analysis
Analyses were conducted using SPSS 24 (IBM, New York, 
NY). Baseline characteristics were compared between pro-
tocols, and descriptive analysis was used to report data per 
group. The statistical significance of continuous data—
which were all non-parametric—between the groups was 
assessed using the Mann–Whitney U-test. The statistical 
significance of categorical variables was assessed using a 
Chi-square or Fisher’s exact test. Next, multivariate analy-
sis was performed. A binary logistic regression model was 
developed to identify the factors that were associated with 
success after a single protocol run. The model included 
covariates that showed an association in the univariate analy-
sis of P < 0.5 or factors known to contribute to success from 
previous studies. A stepwise forward method was used to 
determine the optimal multivariate model. P values of < 0.05 
were considered to be statistically significant. Unadjusted 
and adjusted odds ratios (OR) were reported with 95% con-
fidence intervals (CI).
Results
Subject identification and baseline characteristics
In total, 91 subjects who had been treated for FRI were iden-
tified: 49 for protocol A and 42 for protocol B. Ten subjects 
per protocol were excluded because of major deviation. 
The remaining 71 subjects were eligible for analysis. The 
majority (75%) of subjects were males, with a median age of 
44 years. The pelvis and lower extremities were most often 
affected. The fractures were open in 45% of subjects, and 
most had been treated by nailing or plating (see Table 1). 
Treatment characteristics
Treatment for infection started within a week of the first 
signs of infection in most of the subjects. The median num-
ber of debridements was 2 (1–22) and did not differ between 
both protocols. Local antibiotics were used in 54% and did 
not differ between the two protocols. After debridement, 
54% of the wounds were primarily closed. In protocol B, 
significantly more direct skin or flap transplantations were 
executed (P = 0.009). Furthermore, the median duration of 
both intravenous and oral antibiotic administration differed 
significantly between the protocols (P = 0.000). However, 
the median total duration of the antibiotic treatment was 
80 days (7–202) and did not differ significantly (P = 0.235; 
see Table 2). 
Success
Primary success was achieved in 72% of the subjects in pro-
tocol A and in 47% in protocol B (P = 0.033). The overall 
success rate was 90% and 78%, respectively, for each pro-
tocol. The time between trauma and success did not dif-
fer statistically between protocols, with a median duration 
of 7 months (range 2–37) in protocol A and a median of 
16 months (range 1–35, P = 0.097) in protocol B. In contrast, 
the time between infection and success differed significantly, 
with 5 months (range 2–25) for protocol A and 14 months 
(range 1–33) for protocol B (P = 0.007; see Table 3).
Several variables were selected for logistic regression, 
and were key elements from both treatment protocols, or 
factors associated with a decreased chance of success as 
determined in the literature. The patient-related elements of 
gender, age, Gustilo grade and polytrauma were included, 
as were the key elements of protocol, primary closure, 
rifampicin treatment and duration of antibiotic treatment. A 
step-by-step logistic regression was performed and resulted 
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Table 1  Baseline characteristics and association between multiple patient-related factors and protocol
Bold P values are < 0.05 and considered significant
Data are presented as the number of cases or as median with the range in parenthesis
a Pearson Chi-square
b Fisher’s exact
c Mann–Whitney U-test
Variable Total (n = 71) Protocol P value Missing
A (n = 39) B (n = 32)
Patient
 Age (years) 44 (17–73) 45(18–69) 38 (17–73) 0.278c 0
 Male gender 53 29 24 0.951a 0
 Smoking 28 17 11 0.749a 6
 Comorbidities
  Diabetes mellitus 8 4 4 1.0b 0
  Psychiatric disorder 18 9 9 0.627a 0
 Multitrauma 32 20 12 0.246a 0
 NSAID use during treatment 52 27 25 0.278a 1
 Oral corticosteroid use 4 1 3 0.310b 2
Follow-up (months) 15 (2–111) 11 (3–32) 23 (2–111) 0.003c 0
Fracture
 Localization 0.092b 0
  Sternum/costa 1 1 0
  Humerus 2 1 1
  Radius/ulna 6 3 3
  Pelvic ring/acetabulum 12 8 4
  Femur 15 7 8
  Tibia/fibula 19 11 8
  Ankle 8 6 2
  Foot 8 2 6
 Soft tissue injury 0.075a 1
  Closed and Gustilo I 47 29 18
  Gustilo II and III 23 9 14
Fracture fixation
 Treatment before definite fixation 0.712b 0
  Cast 5 4 1
  External fixation 15 7 8
 Time until fixation 0.001a 3
  0–6 h 19 3 16
  6–24 h 13 10 3
  1–7 days 13 10 3
  > 1 week 23 13 10
 Type of osteosynthesis 0.514b 0
  Zuggurtung/K-wire 3 1 2
  Screws 10 4 6
  Nail 18 9 9
  Plate 40 25 15
 Closure 0
  Primary closure 56 30 26 0.952a
  Direct free flap transplantation 4 2 2 1.0b
  Secondary closure, including vacuum therapy 11 4 7 0.204b
  Time until secondary closure, days 129 (3–399) 79 (3–399) 195 (22–276) 0.592c
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in a simple model with the different protocol elements 
adjusted for both age and Gustilo grade. The other factors 
did not contribute significantly. Because of the limited num-
ber of patients with failure of success included in this study, 
in order to retain optimal adjustment, no further covariates 
were added. The crude and adjusted ORs and 95% CI for 
success for each protocol element are presented in Table 4. 
The separate elements of the protocols did not yield statisti-
cal significance for the prediction of success after adjust-
ment treatment with rifampicin was significantly associated 
with success (OR 3.28, CI 1.03–10.5, P = 0.045). Treatment 
according to protocol A predicted a higher chance of success 
than with protocol B (OR 2.89, CI 1.08–7.72, P = 0.035) and 
remained significant after adjustment for age and Gustilo 
grade (OR 3.45, CI 1.13–10.52, P = 0.030). After adjust-
ment for age and Gustilo classification, the administration 
of rifampicin contributed to higher success rates (OR 3.28, 
CI 1.03–10.5, P = 0.045). Primary closure and the duration 
of antibiotic treatment did not contribute to different success 
rates (see Table 4).
Table 2  Baseline characteristics and association between variables of treatment of the infection and protocol
Bold P values are < 0.05 and considered significant
Data are presented as the number of cases or as median with the range in parenthesis
a Pearson Chi-square
b Fisher’s exact
c Mann–Whitney U-test
d Local antibiotics consisted of either gentamicin-loaded beads, cement, or bioresorbable films in both protocols and were administered at assess-
ment of the treating physician
e Overlap with secondary closure and skin or flap transplantation
f Outliers in wound closure in both groups were due to small skin defect with diminished wound-healing tendencies. Vacuum or antibiotic ther-
apy was not indicated for the total duration needed for closure
Treatment variable Total (n = 71) Protocol P value Missing
A (n = 39) B (n = 32)
Duration symptoms of infection before treatment 0.146b 0
 < 1 day 13 8 5
 1–7 days 47 28 19
 1–3 weeks 11 3 8
Number of debridements performed 2 (1–22) 2 (1–14) 3 (1–22) 0.209c
Local Antibiotics with  debridementd 38 19 19 0.370a 0
Closure after debridement 0
 Primary closure 38 21 17 0.952a
 Secondary closure 24 17 7 0.952a
 Transplantation (flap/skin) 9 1 8 0.009b
 Vacuum  therapye 291 12 17 0.057a
 Time to secondary closure after debridement,  daysf 59 (6–540) 75 (9–540) 26 (6–214) 0.101c
Antibiotic therapy 0
 Duration i.v. antibiotic therapy 17 (7–116) 10 (7–116) 28 (7–110) 0.000c
 Duration oral antibiotic therapy 57 (0–119) 70 (0–112) 28 (0–119) 0.000c
 Duration total antibiotic therapy 80 (7–202) 81 (7–126) 64 (14–202) 0.235c
 Duration of rifampicin therapy 42 (0–116) 80 (7–116) 0 (0–93) 0.000c
Table 3  Association between treatment outcome and protocol
Bold P values are < 0.05 and considered significant
Data are presented as the number or as median with the range in 
parenthesis
a Pearson Chi-square
b Fisher’s exact
c Mann–Whitney U-test
Baseline Protocol P value
(n = 71) A (n = 39) B (n = 32)
Primary success 43 28 15 0.033a
Overall success 60 35 25 0.204b
Time from trauma 
until success 
(months)
10 (1–37) 7 (2–37) 16 (1–35) 0.097c
Time from infec-
tion until suc-
cess (months)
7 (1–33) 5 (2–25) 14 (1–33) 0.007c
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Microbial culture and resistance
Cultures were obtained from 70 subjects, of which five 
showed no growth. Of the positive cultures, 43 showed 
Staphylococcus aureus, of which 29 were monomicrobial 
and 13 were found in polymicrobial cultures. Nine cases 
exhibited monomicrobial cultures with other bacteria 
(Table 5). Follow-up cultures were obtained in 56 subjects 
(79%), with 44 positive cultures with comparable distribu-
tion as the initial cultures. There was no significant differ-
ence in the bacteria cultured (e.g., S. aureus, CoNS, pol-
ymicrobial) in the two protocols (P = 0.213), nor did the 
percentage of initial or follow-up resistance differ (P = 0.969; 
Tables 6, 7). In protocol A, vancomycin was effective in 85% 
of the cases (29/34 positive cultures) for all or part of the 
cultured bacteria. Protocol A showed more rifampicin resist-
ance and protocol B more amoxicillin/clavulanic acid resist-
ance, corresponding to the antibiotics prescribed regularly 
in the respective protocols.  
Discussion
The aim of this study was to compare the effect of two stand-
ardised treatment regimens for (sub)acute FRI that were sim-
ilar in their philosophy for aggressive surgical debridement 
and implant retention, but differed in their use of antibiot-
ics. The immediate administration of an antibiotic directed 
against the most common pathogens in combination with 
rifampicin seemed to contribute to a higher rate of success. 
In addition, an early change to oral antibiotics did not lead 
to worse outcomes in terms of success or antibiotic resist-
ance in protocol A. However, as these elements are totally 
integrated in the protocols, their individual effects cannot 
be distinguished based on this data. Despite better logistics 
and earlier soft tissue coverage in protocol B, the primary 
success rate was significantly higher in protocol A (A = 72% 
and B = 47%), which could be attributed to the treatment 
protocol as a whole and the liberal use of rifampicin (adj-
OR 3.45, CI 1.13–10.52). As the antibiotic strategy was the 
most prominent difference between the two protocols in 
the logistic regression analysis, this supports the argument 
for the early use of empirical antibiotics in the treatment of 
acute FRI.
As evidenced in our study, the majority of bone and joint 
infections are caused by gram-positive bacteria, with S. 
aureus as the most common [3, 9]. However, in the case 
of the exogenous infection of a fracture site, for example 
in open fractures or perioperative contamination, CoNS are 
more common. This is thought to be due to contamination 
by skin flora and the increased pathogenicity of low-virulent 
microorganisms caused by the presence of the implant mate-
rial [13, 14] and/or the decreased microperfusion of injured 
tissue. In our study, a relatively high number of patients with 
polymicrobial cultures were observed [3]. This could be due 
not only to the relatively high number of complicated frac-
tures, but also to the contamination of superficial wound 
swabs. Therefore, for future microbiological identification, 
only deep tissue samples are recommended [15]. Nonethe-
less, we studied two protocols that represented clinical prac-
tice, and as the scope of this study was the effect of the treat-
ment rather than the microbiological identification, we chose 
not to exclude swab samples from this study. Biofilm-form-
ing bacteria are a common cause of FRI and require special 
attention in terms of a treatment approach [8]. For example, 
planktonic S. aureus can begin to form a biofilm within 24 h. 
In a biofilm, bacteria form an extracellular matrix—which 
hinders antibiotic penetration—and enter a stationary growth 
phase, resulting in decreased antibiotic susceptibility [16]. 
We attempted to exclude infections with mature biofilms by 
limiting the study to acute infections (< 3 weeks). However, 
it is possible that, as more delayed infections were included 
in protocol B, dormant infections led to the unnoticed matu-
ration of biofilm before symptoms occurred. If this is the 
case, it could have contributed to the lower primary success 
rates in protocol B. It has been recognised that the success-
ful treatment of mature biofilm infections consists not only 
of antimicrobial, but also of a surgical approach to reduce 
bacterial load, for which implant replacement is sometimes 
necessary [13]. Biofilms in their early stages (< 10 days) 
are significantly less resilient to antibiotic eradication than 
Table 4  Crude and adjusted 
odds ratios of key elements 
of the treatment protocols and 
success
Bold P values are < 0.05 and considered significant
a Adjusted odds ratios were all adjusted for age and Gustilo classification
Regimen variable Crude odds ratio Adjusted odds  ratioa
OR 95% CI P value OR 95% CI P value
Total protocol A 2.89 1.08–7.72 0.035 3.45 1.13–10.52 0.030
Primary closure 2.61 0.98–6.94 0.055 2.09 0.73–5.98 0.171
Rifampicin treatment 2.52 0.92–6.93 0.073 3.28 1.03–10.5 0.045
Duration of total antibi-
otic treatment
0.99 0.97–1.0 0.136 0.99 0.97–1.01 0.208
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older biofilms [17]. The appropriate antibiotic treatment 
has been demonstrated to be able to eradicate young bio-
films entirely without the need for mechanical reduction 
of the biofilm [18–20]. The use of local antibiotics permits 
immediate availability and may thereby contribute to the 
eradication or destabilisation of young biofilms [21]. Thus, 
with a vigorous antibiotic approach directly following ini-
tial debridement, one might maintain control of the local 
situation. As the majority of implant-related infections are 
caused by Staphylococci, empirical therapy must possess 
antimicrobial properties for at least gram-positive bacteria.
Rifampicin is an example of an antibiotic with favourable 
pharmacokinetic properties for biofilm infections because of 
its high bioavailability and capacity to affect bacteria in the 
stationary phase [22]. A disadvantage of rifampicin use is 
the quick emergence of (cross-)resistance, mainly when it 
is administered as monotherapy or in cases with high bacte-
rial load [23, 24]. In this study, we found one new case of 
rifampicin resistance. This low rate of emergence of new 
resistance is in line with the literature, as rifampicin was 
not administered as monotherapy in either of the protocols, 
and thorough surgical debridement minimalised bacterial 
load prior to administration. Although we believe that the 
addition of rifampicin to the antibiotic therapy makes a val-
uable contribution, perhaps stricter indications should be 
maintained.
Amoxicillin/clavulanic acid resistance was found most 
frequently in the patients who had been treated according to 
protocol B, in line with the most frequent administration of 
this drug in the corresponding protocol. Resistance emerged 
twice in Escherichia coli. With high rates of the prescription 
of antibiotics in primary care facilities, the resistance of bac-
teria is a growing problem [25]. Although the Netherlands 
has relatively low bacterial resistance, broad-spectrum peni-
cillin, like amoxicillin/clavulanic acid, is prescribed most 
often and correlates with higher resistance rates [25]. Stud-
ies have demonstrated that amoxicillin/clavulanic acid resist-
ance in E. coli has risen to 14% in the past decades [26]. In 
addition, resistance has been observed in commensal skin 
flora, such as wild-type S. aureus and epidermidis, which 
have 5% and 14% resistance against rifampicin, respectively 
[27]. Taking this into account, we are unable to claim with 
certainty whether our findings demonstrate the emergence 
of new resistance or merely reflect the selection of already 
present resistant mutants. Furthermore, in 40% of the cases, 
there was no information on follow-up cultures (20% miss-
ing, 20% negative cultures), and thus definitive statements 
on the emergence of resistance could not be made.
Both protocols were intended to achieve early surgical 
debridement and wound closure at the initial fracture fixa-
tion. Several studies have described the benefits of primary 
closure in fracture treatment. Both Scharfenberger et al. 
[28] and Jenkinson et al. [29] showed that there are lower Ta
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infection and non-union rates in primary closures after open 
fractures than after delayed closures. In our study, we did not 
find any advantages of primary closure. The high numbers 
of primary closures, as intended in both protocols, may have 
hindered statistical significance in this cohort.
When primary closure was feasible, a drain was left in 
protocol B. This has been considered in the literature to 
have both advantages (fluid and hematoma drainage) and 
disadvantages (a conduit to the external environment) [30]. 
Parker et al. [31] showed in a meta-analysis that there is 
no benefit to closed suction drainage after orthopaedic 
surgery in terms of infection, hematoma, dehiscence or re-
operations, while they demonstrated that there is a higher 
requirement for blood transfusion when drains are applied 
[31]. When primary closure could not be achieved, direct 
flap coverage was preferred in protocol B and vacuum dress-
ing in protocol A, with secondary wound healing or delayed 
flap coverage in extensive soft tissue damage. Direct flap 
coverage of severe soft tissue injuries that accompany frac-
tures can be executed safely, whereas delayed (> 72 h) free 
flap transplantation may be associated with more wound 
complications [32, 33]. Conversely, others have advocated 
that staged soft tissue management minimises swelling and 
thereby reduces post-reconstructive wound complications 
[34]. Vacuum dressing may contribute to reduction in the 
need for flap transfer, size and reoperation, but uncertainty 
exists as to whether the beneficial effects extend beyond the 
first week after initiation [35]. In this cohort, we could not 
confirm nor counter these findings.
There are some limitations to this study. Since this was a 
retrospective cohort, although patients’ baseline characteris-
tics were similar, fracture treatment characteristics were not 
standardised. This resulted in differences in, e.g., free flap 
transplantations (timing/frequency) and time until definitive 
fixation that could not be analysed separately because of 
their small numbers and integration in the rest of the proto-
col. This also applies to the analysis of the independence of 
separate elements of antibiotic treatment. The major differ-
ences between the two protocols were the timing of the start 
and the choice of antibiotics. Both, protocol A, as a whole, 
and the rifampicin treatment, as a separate element, were 
predicted to have higher success rates. However, due to the 
limited number of failures in this study and the incorporation 
of the rifampicin in protocol A, the aforementioned elements 
Table 6  Microbiological 
resistance per protocol
a Pearson Chi-square
b Fisher’s exact
c The numbers of samples (denominator) indicated in the second column are all the positive cultures on 
which susceptibility testing was applicable. In the missing cases susceptibility testing was not performed 
on the prescribed antibiotics. Positive samples per hospital were presented as a fraction of total tested for 
susceptibility
Microbiological variable No. samples for 
analysis (n)c
Protocolc P value Missing
A B
Initial resistance 69 5/38 1/31 0.213b 0
Initial rifampicin resistance 46 1/28 0/8 1.0b 10
Follow-up resistance 42 2/16 5/25 0.685b 1
Follow-up rifampicin resistance 24 2/11 0/5 1.0b 8
Overall resistance 69 6/38 5/31 0.969a 0
Overall rifampicin resistance 47 3/31 0/8 1.0b 9
Table 7  Microbiological resistance per bacterium
All bacteria cultured which showed resistance for administered anti-
biotics were included in this table
Antibiotics indicated with an astrisk (* respectively **) were overlap-
ping in resistance patterns in initial and follow-up resistance
a Although most wild-type strains of Enterobacter cloacae are amox-
icillin-clavulanic acid resistant, in this case a susceptible strain was 
cultured before resistance emerged
Micro-organism Antibiotic Protocol
Initial resistance
 CoNS Ciprofloxacin A
 Staphylococcus epidermidis Ciprofloxacin, rifampicin* A
 Enterobacter gergoviae Amoxicillin/clavulanic acid A
 Stenotrophomonas malt-
ophilia
Ciprofloxacin A
 Staphylococcus epidermidis Tetracyclin A
 Staphylococcus aureus Cefazolin** B
Follow-up resistance
 CoNS Rifampicin A
 Staphylococcus epidermidis Flucloxacillin, rifampicin* A
 Enterobacter cloacaea Amoxicillin/clavulanic acid B
 Escherichia coli Amoxicillin/clavulanic acid B
 Staphylococcus aureus Clindamycin B
 Staphylococcus aureus Cefazolin** B
 Escherichia coli Amoxicillin/clavulanic 
acid, ciprofloxacin
B
The effect of early broad‑spectrum versus delayed narrow‑spectrum antibiotic therapy on the…
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could not be analysed separately. Second, not all patients 
had routine follow-up cultures. Although all clinically rel-
evant, redebridement or protracted infection follow-up tissue 
samples were obtained, additional samples from all treated 
patients could contribute to further insight into resistance 
patterns. Last, the follow-up time was significantly longer 
in protocol B. Although this is mostly explained by the pro-
longed inclusion period and longer time-until-success, it 
may lead to higher relapse rates and thereby result in lower 
success rates for protocol B. In addition to methodological 
limitations, since the execution of this study, a consensus on 
the definition of FRI has been reached and published [15]. 
Although this study did not adhere to the strict criteria for-
mulated in the consensus paper, it reflects clinical practice 
at the time in question, and its findings are still valuable.
In conclusion, overall success rates were high in this set-
ting, where source control and soft tissue coverage were the 
basis of both treatment protocols. Direct empirical combi-
nation antibiotic therapy that consisted of vancomycin and 
rifampicin yielded higher success rates than delayed narrow-
spectrum antibiotics. It is also evident that the former treat-
ment can be used safely, as both protocols had low rates of 
emerging bacterial resistance. Early combination antibiotics 
that are directed at the most common pathogens should be 
considered as the standard of care in acute FRIs.
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